[Extended preoperative speech audiometric diagnostics for cochlear implant treatment]

[人工耳蜗植入术前言语听力检查的扩展]

阅读:1

Abstract

BACKGROUND: For severe hearing loss and even profound deafness, cochlear implants (CIs) have become the treatment of choice. For establishment of the CI indication, the preoperative Freiburger monosyllabic word recognition (EV) at 65 dB SPL in free field with a hearing aid (EV(HG)65) and the maximal understanding (mEV) without a hearing aid with headphones results are important. The goal of this retrospective study was to analyse the correlation of word recognition with a hearing aid at 80 dB SPL (EV(HG)80) and mEV. This represents an extension to measuring EV(HG)65 compared to mEV and to pure-tone audiometry (4FPTA). METHODS: In this study, word recognition with and without a hearing aid was retrospectively analysed for 661 ears. Inclusion criterium was CI implantation at a later date. RESULTS: During preoperative CI diagnostics, an mEV of 0% was found in 334 ears. The EV(HG)65 for 485 ears and the EV(HG)80 for 335 ears were also 0%. The EV with hearing aid was found to worsen with increasing 4FPTA at both sound pressure levels, although this effect was smaller at 80 dB SPL than at 65 dB SPL. Including only ears with mEV > 0 % (N = 260 ears), a stronger correlation between EV(HG)80 and mEV with a difference of (-4.0 ± 16.4%) in comparison to EV(HG)65 and mEV with a difference of (-18.3 ± 16.7%) is seen. This shows a significant difference between mEV and EV(HG)80 compared to mEV and EV(HG)65. CONCLUSION: At a sound pressure level of 65 dB SPL, EV with hearing aid often does not show the accordance with mEV specified by hearing aid and CI guidelines. The EV(HG)80 correlates better with mEV than EV(HG)65. For clinical diagnosis it is rational to measure speech discrimination with hearing aid at levels higher than 65 dB SPL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。